EDIT (Editas Medicine) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EDIT Editas Medicine Inc EDIT
56 GF Score
Price $2.91
GF Value $2.06
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Editas Medicine Net Loan?

Net Loan only applies to banks and insurance companies.

EDIT
56GF Score
Editas Medicine Inc EDIT
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Editas Medicine (EDIT) Overvalued in 2026?

Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued. The current stock price of $2.91 is trading 41.3% above its estimated GF Value™ of $2.06. GuruFocus considers Editas Medicine to be Significantly Overvalued.

Key valuation signals for EDIT:

  • Net Loan:
  • GF Value™: $2.06 vs. price of $2.91 (41.3% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Editas Medicine Business Description

Other Exchanges 0IFK:UK8EM:Germany
Address 11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that develops genomic medicines based on CRISPR gene-editing technology. Its platform uses Cas9 and Cas12a enzymes delivered via lipid nanoparticles or adeno-associated viral vectors to make precise edits in cells. The company's lead programs target sickle cell disease and beta-thalassemia through ex vivo editing of hematopoietic stem cells, alongside earlier-stage in vivo efforts in ophthalmology and other therapeutic areas. Editas pursues both proprietary development and collaborations with larger pharmaceutical partners, from which it earns research funding, milestone payments, and potential royalties. It has no approved products and generates no product revenue, relying on partnership income, licensing, and equity financing to fund research and clinical trials. The company operates primarily in the United States and competes with other gene-editing and gene-therapy developers.
56GF Score

Get the complete analysis for EDIT

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.91
Price
$2.06
GF Value